24/7 Market News Snapshot 26 June, 2025 – bioAffinity Technologies, Inc. Common Stock (NASDAQ:BIAF)

June 26, 2025

DENVER, Colo., 26 June, 2025 (www.247marketnews.com) – (NASDAQ:BIAF) are discussed in this article.
BioAffinity Technologies, Inc. (BIAF), a trailblazer in cancer diagnostics and therapies, is witnessing a remarkable surge in its stock price, which has jumped to $0.375 in pre-market trading, marking a 53.06% increase from the previous close of $0.245. This bullish trend is bolstered by a considerable trading volume of 30.42 million shares, indicating strong investor interest. The company’s stock movement indicates potential momentum, attracting the attention of traders and analysts as it could be positioned for further gains.

In parallel, BioAffinity recently showcased its commitment to innovation at the RNA Therapeutics Conference, where it presented groundbreaking findings in cancer treatment. The presentation, titled “Silencing CD320 and LRP2 by siRNAs selectively kills cancer cells: mechanistic enigmas,” highlighted the company’s pioneering approach utilizing small interfering RNAs (siRNAs) to effectively target and destroy cancer cells without harming healthy surrounding tissues.

The research drew from findings related to the recently issued U.S. Patent No. 12,305,171, demonstrating that dual suppression of cell surface receptors CD320 and LRP2 significantly impacts cancer cell viability. This advancement signifies a breakthrough in RNA-based cancer therapies, with potential applications across various tumor types, including lung, breast, prostate, and skin cancers.

Dr. David Elzi, Vice President of Product Development, asserted the transformative potential of these findings for targeted therapeutic applications. Meanwhile, BioAffinity’s President and CEO, Maria Zannes, reiterated the company’s dedication to pioneering healthcare solutions. She highlighted the significance of such scientific engagements in reinforcing BioAffinity’s mission to offer innovative and effective cancer treatments. This dual momentum in market performance and groundbreaking scientific developments positions BioAffinity Technologies favorably for future growth and advancement in the biotechnology arena.

Related news for (BIAF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.